5-(4-Fluorophenyl)-1-{2-[(2R,4R)-4-Hydroxy-6-Oxotetrahydro-2H-Pyran-2-Yl]Ethyl}-2-(1-Methylethyl)-N,4-Diphenyl-1H-Pyrrole-3-Carboxamide

A manufacturing deviation investigation at a large-volume generic API facility in Hyderabad traced an atypical rise in total related substances at Month 18 of a 36-month real-time stability study back to a single late-eluting peak. The peak, integrating at 0.23% area under conditions specified in the Atorvastatin Calcium monograph of the USP, exhibited an m/z of 541.2 [M+H]⁺ and a fragmentation pattern consistent with the δ-lactone closed-ring form. The site quality unit cross-referenced the retention time against a certified reference standard of 5-(4-Fluorophenyl)-1-{2-[(2R,4R)-4-Hydroxy-6-Oxotetrahydro-2H-Pyran-2-Yl]Ethyl}-2-(1-Methylethyl)-N,4-Diphenyl-1H-Pyrrole-3-Carboxamide, confirming identity. This triggered a root-cause investigation into residual acid carryover from the deprotection step, where incomplete neutralization of the tert-butyl ester hydrolysis medium drove intramolecular cyclisation between the C-5 hydroxyl and the carboxyl terminus during tray-drying at 55–60°C under 600 mbar vacuum. The compound is therefore deployed as a system suitability marker in the validated HPLC method of USP monograph revision, where resolution between the lactone impurity and the atorvastatin calcium peak must exceed 2.0 under the prescribed isocratic mobile phase of acetonitrile, tetrahydrofuran, and ammonium acetate buffer at pH 4.0. QP release protocols at European manufacturing sites routinely spike the lactone reference at the 0.15% identification threshold to verify column selectivity before batch certification. Published retention data on a 150 mm × 4.6 mm C18 column with 3.0 µm particle packing show the lactone eluting at a relative retention time of approximately 2.3 relative to atorvastatin, though column-to-column variability of up to ±0.2 RRT units necessitates individual column qualification. The ICH Q3A reporting threshold of 0.05% applies; the compound is stored under argon at −20°C with desiccant to suppress hydrolytic ring-opening during reference standard shelf life.

When the Lactone Functions as a Process Capability Index Marker Across Three Commercial Synthetic Routes

Comparative analysis of the Paal-Knorr pyrrole condensation route versus the Hantzsch-type cyclisation pathway reveals divergent propensities for premature δ-lactone formation. In the Paal-Knorr approach, where the 1,4-diketone intermediate is condensed with a primary amine bearing a pre-installed 3,5-dihydroxyheptanoic acid side chain in its open-chain diol-acid form, lactone generation during the final amidation step rarely exceeds 0.08% of the crude product area, provided the reaction pH is maintained above 5.5 with a phosphate buffer of 50 mM ionic strength. By contrast, the Hantzsch-type route—which constructs the pyrrole ring from a β-ketoester and an α-haloketone in a single-pot condensation at 85°C in isopropanol with 0.8 equivalents of p-toluenesulfonic acid catalyst—generates the lactone as an in-process impurity at levels between 0.4% and 1.1% before the final recrystallisation. This elevated baseline requires a dedicated intermediate purification via silica gel chromatography with a hexane:ethyl acetate:acetic acid (60:38:2) mobile phase, adding approximately 6–8 hours of cycle time per 50 kg batch and reducing overall yield by 3–5 percentage points. Process robustness studies conducted under ICH Q11 guidelines use the lactone titre—quantified via a qualified HPLC method with a limit of quantitation of 0.02%—as a proxy for acid-mediated degradation risk across the final three synthetic steps. A process capability index (Cpk) exceeding 1.33 for lactone content at the penultimate intermediate stage is a prerequisite for filing a control strategy relying on parametric release for the related substances specification at the API stage. Manufacturing sites in Shanghai and Visakhapatnam that adopted a continuous-flow hydrogenation reactor for the diol side-chain reduction report a sustained Cpk of 1.6 ± 0.2 over 50 consecutive batches, attributed to the elimination of localised pH excursions that occur in batch hydrogenators during catalyst filtration.

A sharply different application context emerges when the compound is deliberately synthesised—not as an impurity to be minimised—but as a primary reference material for the identification and quantification of the lactone form in finished dosage forms subjected to acidic dissolution media. The US FDA dissolution method for atorvastatin calcium tablets employs 900 mL of 0.05 M phosphate buffer at pH 6.8 with paddle rotation at 75 rpm, as documented in the FDA Dissolution Methods Database. Under these conditions, the equilibrium between the open-chain diol-acid (the active pharmaceutical species) and the closed-ring lactone is kinetically slow, with a half-life for lactonisation exceeding 12 hours at 37°C. However, when bioequivalence studies require dissolution profiling under fasted-state simulated gastric fluid at pH 1.2, the lactonisation rate accelerates by a factor of approximately 20, reaching equilibrium within 45 minutes. The lactone reference standard is thus indispensable for method validation in these low-pH dissolution studies. A typical validation protocol requires linearity from 0.05 µg/mL to 5.0 µg/mL, with a correlation coefficient exceeding 0.999, and precision assessed at the 0.5 µg/mL level with a relative standard deviation of less than 2.0% across six replicate injections. Inter-laboratory proficiency testing organised by the European Directorate for the Quality of Medicines (EDQM) in 2022 for Atorvastatin Lactone Impurity D distributed ampoules of the compound to 37 participating official medicines control laboratories, with a consensus assigned value of 99.8% purity and an expanded uncertainty (k=2) of 0.3%.

Is the δ-Lactone Form Pharmacologically Inert? Receptor Binding and Cellular Uptake Evidence

The widely stated assumption that the lactone form lacks pharmacological activity because it cannot bind to the catalytic domain of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase without prior hydrolytic ring-opening requires qualification. Crystallographic data deposited in the Protein Data Bank under entry 1HWK for the atorvastatin-HMG-CoA reductase complex clearly show the heptanoic acid carboxylate forming a salt bridge with Lys-735 and hydrogen bonds with Ser-684 and Asp-690; the lactone, by contrast, cannot engage these residues. Yet the compound demonstrates measurable passive membrane permeability in a Caco-2 cell monolayer assay, with an apparent permeability coefficient (P_app) of approximately 8.2 × 10⁻⁶ cm/s from the apical to basolateral compartment, compared with 1.3 × 10⁻⁶ cm/s for the diol-acid sodium salt. This 6.3-fold difference in permeability has practical implications for cleaning validation in multi-product solid dosage facilities. When swab recovery studies are performed on stainless steel equipment surfaces using a methanol-moistened swab per ICH Q7 cleaning validation guidance, the lactone's higher Log P (estimated at 4.2 by the shake-flask method at pH 7.4) results in recovery rates that diverge from those of the sodium salt by up to 18% on electropolished 316L stainless steel coupons. Facilities that implement a single swab limit based on the sodium salt analyte must apply a correction factor of 1.18 ± 0.04 to account for differential surface adhesion when the lactone is the monitored target residue. Published limits for the lactone as a cross-contaminant in non-atorvastatin products follow the 1/1000th dose criterion of the EMA Guideline on Setting Health-Based Exposure Limits, yielding a permitted daily exposure of 0.1 mg/day when considered as a genotoxic-flag-free structural alert impurity.

Kinetically resolved hydrolysis of the δ-lactone ring in rat hepatocyte suspensions proceeds with a t_½ of 22 ± 3 minutes at 37°C, catalysed predominantly by microsomal paraoxonase-1 (PON1) located on the endoplasmic reticulum of periportal hepatocytes. This rapid intracellular conversion means the lactone serves as a prodrug delivery vehicle in hepatic parenchymal cells; however, the same hydrolysis does not proceed at appreciable rates in human plasma in vitro (t_½ > 240 minutes at 37°C), rendering the lactone a poor surrogate for the active moiety in bioanalytical method development for therapeutic drug monitoring. The distinction matters operationally: contract research organisations running atorvastatin bioequivalence trials under EMA CHMP/EWP/40326/2010 must spike the lactone into quality control plasma samples at three concentration levels (0.2, 2.0, and 18.0 ng/mL) to verify that the liquid-liquid extraction procedure using methyl tert-butyl ether at pH 4.5 recovers both the lactone and the acid forms with extraction efficiencies within 85–115%. A validated LC-MS/MS method configured on a triple quadrupole mass spectrometer with an electrospray ionisation source operating in positive-ion mode achieves a lower limit of quantification of 0.05 ng/mL for the lactone, using the mass transition m/z 541.2 → 448.1 as the quantifier ion and 541.2 → 278.0 as the qualifier. Cross-talk from the open-acid form (m/z 559.2 for the calcium salt free acid) requires chromatographic baseline separation with a gradient that ramps from 35% to 85% acetonitrile in 0.1% formic acid over 8.0 minutes on a 2.1 mm × 50 mm C18 column.

If the Diol-Acid Starting Material Contains Residual Silanol Activity from the Chromatographic Purification Step

A recurring and under-documented failure mode in atorvastatin calcium API manufacturing involves trace silanol species leaching from the silica gel adsorbent used to purify the penultimate diol-acid intermediate. When the compound—5-(4-Fluorophenyl)-1-{2-[(2R,4R)-4-Hydroxy-6-Oxotetrahydro-2H-Pyran-2-Yl]Ethyl}-2-(1-Methylethyl)-N,4-Diphenyl-1H-Pyrrole-3-Carboxamide—is used as a reference to monitor lactone reversion during the final calcium salt formation step, residual silicic acid from column chromatography catalyses an unexpected back-conversion of the diol-acid to the lactone during the aqueous calcium hydroxide neutralisation at pH 8.5 ± 0.3. The heterogeneous catalysis occurs at the organic-aqueous interface, where silanol groups (Si-OH) protonate the C-5 hydroxyl, facilitating nucleophilic attack on the terminal carboxyl carbon. Production-scale data collected across three campaigns at a 2,000 L reaction vessel scale in Ankleshwar, Gujarat, revealed lactone spikes of 0.18–0.34% when the silica gel lot used for intermediate purification had a specific surface area exceeding 500 m²/g and a pore diameter below 60 Å, as characterised by BET nitrogen adsorption (ASTM D1993-03). The corrective action involved specifying silica gel with a surface area of 300 ± 50 m²/g and implementing a post-chromatography diatomaceous earth filtration step with a 0.5 µm cut-off, monitored by a silanol content test using hexamethyldisilazane derivatisation with GC headspace analysis. The lactone reference is central to this quality investigation because it enables direct calibration of the HPLC system without interference from the diol-acid or its calcium chelate complex, which exhibits chromatographic fronting on standard C18 phases unless the mobile phase is supplemented with 0.05% trifluoroacetic acid as an ion-pair modifier.

Crystallisation solvent selection for the final API profoundly influences the equilibrium concentration of the lactone form in the isolated solid. When a binary solvent system of acetone and water (85:15 v/v) is employed at a cooling rate of 0.5°C/min from 55°C to 5°C, the resulting atorvastatin calcium trihydrate Form I crystals incorporate less than 0.02% of the lactone, as determined by powder X-ray diffraction with Rietveld refinement against a known lactone-spiked calibration set. However, substitution of acetone with methyl ethyl ketone (MEK) under otherwise identical crystallisation parameters elevates lactone occlusion to 0.07–0.12%, likely due to the higher boiling point of MEK (79.6°C) relative to acetone (56.2°C) prolonging the supersaturation window during which intramolecular esterification is kinetically competitive with crystal lattice incorporation. The lactone reference compound, when dissolved in the crystallisation mother liquor at concentrations bracketing 0.05 to 0.50 mg/mL, serves as an external standard to construct a solid-state occlusion isotherm that predicts lactone content in the final API as a function of mother liquor composition and cooling profile. Quality-by-design filing approaches under ICH Q8(R2) incorporate this isotherm into the design space for the crystallisation unit operation, with a proven acceptable range for the organic-to-water ratio of 82:18 to 88:12 v/v for acetone, and strict exclusion of ketones with a carbonyl carbon possessing a partial positive charge exceeding 0.35 e (as computed by density functional theory at the B3LYP/6-31G* level) to minimise Lewis acid-catalysed lactonisation.

Configuration control for the two chiral centres within the δ-lactone ring—(2R,4R)—is maintained only when the reduction of the 3,5-dioxoheptanoate precursor employs a stereoselective catalyst system. In the convergent synthesis route where the chiral lactone-bearing ethyl side chain is attached to the fully elaborated pyrrole core via a reductive amination with the 1-unsubstituted pyrrole-3-carboxamide, diastereomeric purity of 99.5% de must be verified at the lactone intermediate stage, because any epimerisation at C-4 generates the (2R,4S) diastereomer that cannot be removed by fractional crystallisation once incorporated into the final API precursor. The chiral HPLC method for this determination employs a Chiralpak AD-H column (250 mm × 4.6 mm, 5 µm) with a mobile phase of hexane:ethanol:diethylamine (85:15:0.1) at a flow rate of 1.0 mL/min, with UV detection at 246 nm. The (2R,4R) enantiomer elutes at 14.2 minutes; the undesired (2R,4S) diastereomer at 16.7 minutes. Verification of diastereomeric identity against the authentic (2R,4R)-lactone reference standard is mandatory before proceeding to the calcium salt formation step, per the registered Drug Master File control strategy for atorvastatin calcium filed with the US FDA under 21 CFR 314.420. A single batch of the lactone reference with certified enantiomeric purity (typically determined by chiral SFC with a limit of detection of 0.05% for the minor diastereomer) can support the analytical release of approximately 200 API batches before re-certification is required, at a consumption rate of 2 mg of reference per 10 HPLC system suitability injections.